secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001104659-23-068540
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals announces $6.28M registered direct offering of common stock and warrants
--------------------------------------------------------------------------------

- Registered direct offering of 9,670,002 shares at $0.65/share for ~$6.28M gross proceeds.
- Concurrent private placement of warrants for 9,670,002 shares at $0.6525/share; exercisable after 6 months for 5 years.
- Existing warrants with exercise prices of $3.07-$12.00 amended to $0.6525 and expiration extended to 5.5 years post-closing.
- Net proceeds to be used for working capital and to initiate NRX-101 research for PTSD and chronic pain.
- Closing expected June 8, 2023; H.C. Wainwright acting as exclusive placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923068540/0001104659-23-068540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923068540/tm2317653d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer